Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of KP104 in complement inhibitor-naive PNH
CTR20222784Phase 2Completed
- Sponsor
- Kira Pharmaceuticals
- Start
- Nov 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KP104 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Kira Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
KP104
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20222784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222784.